Touchstar Share Discussion Threads

[russman] 10/6/2016 13:06

Therefore the Directors did not buy any of the fractions?

[norbert colon] 09/6/2016 13:50

Russman. Check your broker account and you will see the consolidation has been undertaken (basically you will hold fewer shares of a higher 'value'). Number of shares in issue reduced - job done.

[russman] 09/6/2016 12:56

I am getting confused.Have the fractions been sold yet?

[cockerhoop] 07/6/2016 08:57

I imagine Self Trade have a systems issue as it's a new EPIC. I've just carried out dummy trades with idealing no problems.

[value hound] 07/6/2016 08:50

Any idea why Self Trade are telling me I can't buy this stock? It looks good value to me; is the share consolidation not complete yet?

[norbert colon] 27/5/2016 09:02

Packman - legacy shareholding from when he was on the board at Feedback Data before they divested the business to BVM.

[packman8] 26/5/2016 22:33

Feedback director has over a 4% stake. Why?

[hastings] 26/5/2016 15:25

Eps 2016 9.5p and 12.2p next year based on pre-tax £0.6m and £0.8m.

[norbert colon] 26/5/2016 15:16

Noted and correct - pre consolidation figures.

[pugugly] 26/5/2016 15:04

Hastings and or Norbert - PER does not (imo) compute with forward eps in header. Unless eps based on old BVM closing share price. Current TSP share price 60/66p

[hastings] 25/5/2016 10:21

Cheers for starting the thread Norbert.
WH Ireland has a 96p target price which would put the stock on PER of 10.6 falling to 7.5 next year.

[cockerhoop] 24/5/2016 11:43

Norbert,

Regards your question on the previous BB regards attending the Agm, I was tempted but the 9.30 start time put me off - and perhaps others that live outside the Manchester area.

[norbert colon] 24/5/2016 11:12

Change of name effective from 7am tomorrow:

[norbert colon] 24/5/2016 11:09

I have taken the liberty of creating a new thread for Touchstar Technologies (TST), the new name for Belgravium Technologies (BVM).

hxxp://www.touchstar.co.uk

Investment Case / Pro's:

- New Board and streamlined management structure
- Change in name / legacy issues now historic
- Cost reduction programme essentially complete / more efficient and coherent business
- Enviable blue chip client / customer base
- Decent balance sheet
- GBP 1m overdraft now in place with Barclays
- Tax credits due to R&D spend
- Cash generative
- Historically good recurring revenue stream
- Revenue and margin improvement expected
- Good gross margins
- Potential for dividend reinstatement
- Chairman owns 3%+ of the company
- Reasonable Director remuneration
- Operational gearing
- Rationalisation of office space over next 18-24 months should deliver further cost savings

Con's

- Microcap with usual lack of liquidity
- Bid / offer spread
- Competitive market place / need for R&D to keep product offerings desirable
- Successful turnaround of the company yet to be fully proven


Current broker forecast: EPS 10.3p (2016) and 12.6p (2017) based on pre-tax profit of £0.45m and £0.6m respectively. WHI target price of now 103p (upgraded from 96p) as of September 2016.

Issued share capital now 6,308,750 ordinary shares.

[dahmmy] 17/8/2013 20:15

.

..

[dahmmy] 09/8/2013 23:28

.
.

.

.

[dahmmy] 21/2/2013 15:29

Near Term Activities

Siciny-2 DFIT and Frac Mobilization - Performed by Halliburton


-- 24 April 2013 - mill out cement and pressure test the well
-- 27 April 2013 - run vertical seismic profile (VSP)
-- 2 May 2013 - upgrade the well head to 15,000 psi
-- 8 May 2013 - perforate the well, perform DFIT and observe formation pressure for 3-4 weeks
-- Early June 2013 - perform two-stage vertical frac


Czas aw-1 Stimulation and Test - Performed by Schlumberger


-- 25 April 2013 - acid wash and clean out of the well
-- 26-30 April 2013 - acid squeeze into the Main Dolomite reservoir; after soaking lift fluids in the well bore using nitrogen, followed by 3 day flow test up to 400 bbls of oil
-- 1 May 2013 - shut-in the well for 5 day build-up with downhole gauges
-- 6 May 2013 - decision on a long term test and oil production, based upon results of the acid stimulation and test